112 - Novel Vaccination strategies against Respiratory Infections

Friday, October 1, 2021

4:15 PM - 5:30 PM EDT

Moderator(s)

Michael Glickman, MD, FIDSA, FAAM

Member, Attending Physician
Memorial Sloan Kettering
New York, NY, United States

Fimbrion Therapeutics (Individual(s) Involved: Self): Consultant; Pathogen Response Lab (Individual(s) Involved: Self): Board Member; Vedanta Biosciences (Individual(s) Involved: Self): Board Member, Shareholder
Anne-Catrin Uhlemann, MD, PhD

Associate Professor
Medicine/Infectious Diseases
Columbia University Irving Medical Center
New York, NY, United States

Merck (Individual(s) Involved: Self): Grant/Research Support

Speaker(s)

Jay Kolls, MD

John W Deming Endowed Chair in Internal Medicine
Tulane School of Medicine
New Orleans, LA, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Kevin Saunders, PhD

Director of Research
Duke Human Vaccine Institute
Durham, NC, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Stacey Schultz Cherry, PhD

Professor
St. Jude Children's Research Hospital, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:

Michael S. Glickman, MD, FIDSA, FAAM: Fimbrion Therapeutics (Individual(s) Involved: Self): Consultant; Pathogen Response Lab (Individual(s) Involved: Self): Board Member; Vedanta Biosciences (Individual(s) Involved: Self): Board Member, Shareholder

Anne-Catrin Uhlemann, MD, PhD: Merck (Individual(s) Involved: Self): Grant/Research Support

Jay K. Kolls, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Kevin O. Saunders, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Stacey Schultz Cherry, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the potential approaches and likelihood of success of developing a pan influenza vaccine
describe the potential approaches and likelihood of success of developing a pan coronavirus vaccine
describe the major mechanisms of immune protection in the lung and their stimulation by vaccination

Presentations:

Induction of T Cell Immunity in the Lung
Speaker: Jay K. Kolls, MD – Tulane School of Medicine
Progress Toward Universal Coronavirus Vaccines
Speaker: Kevin O. Saunders, PhD – Duke Human Vaccine Institute
Progress Toward Universal Influenza Vaccines
Speaker: Stacey Schultz Cherry, PhD – St. Jude Children's Research Hospital